Updated Results of a Phase II Study: Neoadjuvant Inetetamab Combined with Pertuzumab, Paclitaxel and Carboplatin for Locally Advanced HER2-Positive Breast Cancer

被引：0
|
作者：
Chai, Yue
Liu, Jiaxuan
Jiang, Mingxia
He, Maiyue
Wang, Xin
Wang, Yipeng
Yang, Xue
Wang, Jing
Xu, Binghe
Li, Qiao
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO2-18-12
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO2-18-12
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Neoadjuvant inetetamab combined with pertuzumab, paclitaxel and carboplatin for locally advanced HER2-positive breast cancer: Primary analysis of a phase II study
    Chai, Y.
    Jiang, M.
    Liu, J.
    He, M.
    Wang, X.
    Wang, Y.
    Yang, X.
    Wang, J.
    Xu, B.
    Li, Q.
    ANNALS OF ONCOLOGY, 2023, 34 : S327 - S327
  • [2] Neoadjuvant inetetamab combined with pertuzumab, paclitaxel, and carboplatin (TCbIP) for locally advanced HER2-positive breast cancer: Primary analysis of a phase II study.
    Chai, Yue
    Li, Qiao
    Liu, Jiaxuan
    Jiang, Mingxia
    He, Maiyue
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] A propensity-matched analysis of the efficacy and safety of neoadjuvant inetetamab and pertuzumab with paclitaxel and carboplatin (TCbIP) on locally advanced HER2-positive breast cancer
    Jiang, Mingxia
    Chai, Yue
    Liu, Jiaxuan
    He, Maiyue
    Wang, Yipeng
    Xue, Yang
    Xing, Zeyu
    Zhang, Mengqi
    Zhou, Shihan
    Ma, Fei
    Wang, Jiayu
    Yuan, Peng
    Xu, Binghe
    Li, Qiao
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Neoadjuvant inetetamab and pertuzumab with taxanes and carboplatin (TCbIP) In locally advanced HER2-positive breast cancer: a prospective cohort study with propensity-matched analysis
    Jiang, Mingxia
    Chai, Yue
    Liu, Jiaxuan
    He, Maiyue
    Wang, Yipeng
    Yang, Xue
    Xing, Zeyu
    Zhang, Mengqi
    Zhou, Shihan
    Ma, Fei
    Wang, Jiayu
    Yuan, Peng
    Xu, Binghe
    Li, Qiao
    BMC CANCER, 2024, 24 (01)
  • [5] Neoadjuvant ixabepilone/carboplatin/trastuzumab in HER2-positive locally advanced breast cancer: A Sarah Cannon Research Institute phase II trial
    Zubkus, J. D.
    Daniel, D. B.
    Eakle, J. F.
    Bechhold, R. G.
    Shastry, M.
    Tucker, P. S.
    Burris, H. A.
    Hainsworth, J. D.
    Yardley, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] Neoadjuvant weekly paclitaxel and carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer: a Brown University Oncology Research Group (BrUOG) study
    Lopresti, M. L.
    Bian, J. J.
    Sakr, B. J.
    Strenger, R. S.
    Legare, R. D.
    Fenton, M.
    Witherby, S. M.
    Dizon, D. S.
    Pandya, S. V.
    Stuckey, A. R.
    Edmondson, D. A.
    Gass, J. S.
    Emmick, C. M.
    Graves, T. A.
    Cutitar, M.
    Olszewski, A. J.
    Sikov, W. M.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 189 (01) : 93 - 101
  • [7] Efficacy and tolerability of neoadjuvant Pertuzumab, Trastuzumab, and weekly Paclitaxel in Locally advanced Her-2 positive Breast cancer
    Gupta, Niraj
    Giblin, Erica
    Spivey, Tara
    Govert, Kristen
    Leagre, Christopher
    Liebross, Robert
    Tumati, Vasu
    Dugan, Thomas
    Yadav, Rina
    Henman, Patrick
    Beaudrie, Nick
    Bair, Tessa
    Durk, Jessica
    Hancock, Marjaorie
    Engle, Trisha
    Myers, Michelle
    Schneiders, Julie
    Tigges, Thomas
    CANCER RESEARCH, 2021, 81 (04)
  • [8] Neoadjuvant weekly paclitaxel and carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer: a Brown University Oncology Research Group (BrUOG) study
    M. L. Lopresti
    J. J. Bian
    B. J. Sakr
    R. S. Strenger
    R. D. Legare
    M. Fenton
    S. M. Witherby
    D. S. Dizon
    S. V. Pandya
    A. R. Stuckey
    D. A. Edmondson
    J. S. Gass
    C. M. Emmick
    T. A. Graves
    M. Cutitar
    A. J. Olszewski
    W. M. Sikov
    Breast Cancer Research and Treatment, 2021, 189 : 93 - 101
  • [9] Paclitaxel, Carboplatin, and Trastuzumab in a Neoadjuvant Regimen for HER2-Positive Breast Cancer: The TRAIN Study.
    Sonke, G. S.
    Mandjes, I. A.
    Holtkamp, M.
    Schot, M.
    Oosterkamp, H. M.
    Wesseling, J.
    Vrancken, Peeters M-J T.
    Rodenhuis, S.
    Linn, S. C.
    CANCER RESEARCH, 2011, 71
  • [10] Updated results of a phase II study (M77035) of Myocet® combined with weekly Herceptin® and paclitaxel in patients (pts) with HER2-positive locally advanced or metastatic breast cancer (LABC/MBC).
    Cortes, J
    Climent, M
    Lluch, A
    Hornedo, J
    Gascon, P
    Mayordomo, J
    Gil, M
    Benavides, A
    Reguiero, P
    Trigo, J
    Baselga, J
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S125 - S126
12345